Q32 Bio, Inc.

Third Harmonic Bio and Q32 Bio are not in imminent danger of running out of cash, but both companies recently took a look at early data for their lead drug candidates and decided to significantly cut

Q32 Bio, Inc. has found a route to the public markets through a reverse merger with Homology Medicines, Inc. , one of three transactions it announced 16 November as it positions itself as a public c

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Ovid Taps Gensaic’s Approach To Neurolo

Horizon Therapeutics plc has had the thyroid eye disease (TED) market cornered since launching Tepezza (teprotumumab) in early 2020 and establishing a fast blockbuster drug, but Viridian Therapeutic